Drug Profile
Research programme: diabetic nephropathy therapies - AstraZeneca/Mitsubishi Tanabe Pharma Corporation
Latest Information Update: 28 Sep 2018
Price :
$50
*
At a glance
- Originator AstraZeneca; Mitsubishi Tanabe Pharma Corporation
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic nephropathies
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for research development in Diabetic-nephropathies in Japan
- 28 Sep 2018 No recent reports of development identified for research development in Diabetic-nephropathies in Sweden
- 20 Aug 2014 Early research in Diabetic nephropathies in Sweden and Japan (unspecified route)